Plasma bradykinin in angio-oedema

Juerg Nussberger, Massimo Cugno, Catherine Amstutz, Marco Cicardi, Andrea Pellacani, Angelo Agostoni

Research output: Contribution to journalArticle

Abstract

Background. Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-oedema due to C1 esterase inhibitor deficiency, as well as in angio-oedema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE). Difficulties in the measurement of kinin concentrations, however, have so far precluded the demonstration of an incontrovertible change in plasma bradykinin concentrations in these disorders. By developing a reliable assay we have been able to follow bradykinin concentrations during attacks and during remission in HA and in AA, and also in a patient treated with an ACE-inhibitor. Methods. Liquid-phase extraction, high-performance liquid chromatography, and RIA were used for specific measurement of plasma bradykinin concentrations in 22 patients with HA and in 22 healthy volunteers of similar age and sex distribution. Four patients with AA and one hypertensive patient treated with the ACE inhibitor captopril were also studied. Findings. Among the healthy volunteers plasma bradykinin concentration was inversely proportional to age. The geometric mean plasma bradykinin concentration in the healthy volunteers was 2.2 fmol/mL (SD 2.2), compared with 3.9 fmol/mL (3.7) among patients with HA during remission (p = 0.095). Bradykinin was also high in the patients with AA (10.4 fmol/mL [1.6]). During acute attacks of oedema, in both HA and AA, plasma bradykinin rose to two to 12 times the upper limit of normal. Infusion of C1-esterase inhibitor (the deficient factor in both HA and AA) immediately lowered bradykinin concentrations. In the patient receiving the ACE-inhibitor captopril, bradykinin concentration was very high at 47 fmol/mL during an acute attach of angio-oedema, but normal at 3.2 fmol/mL in remission after withdrawal of the drug. Interpretation. A sensitive method for measurement of plasma bradykinin provided the means to show that concentrations of this peptide decrease with age in healthy people. Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-oedema.

Original languageEnglish
Pages (from-to)1693-1697
Number of pages5
JournalLancet
Volume351
Issue number9117
DOIs
Publication statusPublished - Jun 6 1998

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Plasma bradykinin in angio-oedema'. Together they form a unique fingerprint.

  • Cite this

    Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., & Agostoni, A. (1998). Plasma bradykinin in angio-oedema. Lancet, 351(9117), 1693-1697. https://doi.org/10.1016/S0140-6736(97)09137-X